Sanofi Consumer Healthcare India Posts Strong FY25 Results, Recommends ₹75 Dividend

Revenue from operations surged 21% to ₹878.4 crore, Profit After Tax (PAT) grew 33% to ₹240.1 crore.

Reader Takeaway: Strong growth drivers include cost efficiency and market momentum; regulatory risks and competition are key watch points.

What just happened

Sanofi Consumer Healthcare India announced its financial results for the year ended December 31, 2025. Revenue from operations increased by 21% to ₹878.4 crore, up from ₹724.5 crore in the previous year. Profit After Tax (PAT) saw a significant jump of 33%, reaching ₹240.1 crore compared to ₹181.0 crore in 2024.

The company also maintained a robust EBITDA margin of 36%, attributed to cost management and operational efficiency.

Why this matters

The strong performance indicates successful execution of the company's strategy following its demerger and transition to an independent entity. The growth in both revenue and profit signals market acceptance and effective operational management.

The recommended final dividend of ₹75 per equity share, subject to shareholder approval, reflects management's confidence in the company's financial health and future prospects.

The backstory

This marks the first full year of independent operations for Sanofi Consumer Healthcare India after its demerger. The company has focused on its core portfolio and enhancing digital capabilities.

What changes now

With a solid financial footing, the company is set to continue its growth trajectory. The recommended dividend provides a direct return to shareholders.

Investors will be keenly watching the company's ability to navigate potential pricing pressures and its inclusion in the National List of Essential Medicines (NLEM).

Risks to watch

Potential inclusion in the NLEM and pricing pressures could impact future margins. Increasing competition in the consumer healthcare sector requires sustained investment in brand building and innovation.

Peer comparison

While specific peer comparisons are not detailed in the filing, the company operates in the competitive Indian consumer healthcare market, facing established players and new entrants.

Context metrics (time-bound)

Revenue from operations: ₹878.4 crore (FY25) vs ₹724.5 crore (FY24), a 21% increase.
Profit After Tax (PAT): ₹240.1 crore (FY25) vs ₹181.0 crore (FY24), a 33% increase.
EBITDA Margin: 36% (FY25).
Recommended Dividend: ₹75 per equity share.

What to track next

Investors should monitor the company's performance in managing regulatory changes, competitive intensity, and its continued focus on product innovation and market expansion.